|
Video: What is a Stock Split?
|
|
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Co.'s primary product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells in development for the treatment of Duchenne muscular dystrophy. Co. has also developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. According to our CATB split history records, CATB has had 3 splits. | |
|
CATB (CATB) has 3 splits in our CATB split history database. The first split for CATB took place on December 28, 2018. CATB's second split took place on December 31, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of CATB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. CATB's third split took place on August 20, 2021. This was a 1 for 6 reverse split, meaning for each 6 shares of CATB owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 16.6666666666667 share position following the split.
When a company such as CATB conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CATB split history from start to finish, an original position size of 1000 shares would have turned into 16.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CATB shares, starting with a $10,000 purchase of CATB, presented on a split-history-adjusted basis factoring in the complete CATB split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/26/2015 |
|
End date: |
09/08/2021 |
|
Start price/share: |
$808.20 |
|
End price/share: |
$8.54 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.94% |
|
Average Annual Total Return: |
-51.95% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$105.65 |
|
Years: |
6.21 |
|
|
|
Date |
Ratio |
12/28/2018 | 1 for 1 | 12/31/2018 | 1 for 10 | 08/20/2021 | 1 for 6 |
|
|